文献速递其他结缔组织病

消费者活动追踪器评估肌炎患者体力活动

Consumer-based activity trackers in evaluation of physical activity in myositis patients.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

结果显示Fitbit日步数重测信度强(ICC 0.89),与ActiGraph一致性良好(ICC 0.96),且与疾病活动度和功能测试相关。

要点

  • Fitbit日步数和峰值1分钟步频在肌炎患者中可靠且有效。
  • Fitbit与ActiGraph步数一致性良好(ICC 0.96)。
  • Fitbit有潜力用于临床实践和试验监测体力活动。

核心结论

  • Fitbit日步数和峰值1分钟步频是肌炎患者体力活动的可靠且有效测量指标。

研究设计与样本

  • 试点、概念验证、前瞻性观察研究,在0、1、3、6个月进行四次访视,纳入PM、DM、坏死性肌病(NM)或抗合成酶综合征(AS)受试者。

主要发现

  • 日步数在1个月随访时重测信度强(ICC 0.89)。
  • 日步数和峰值1分钟步频与医生整体疾病活动度、患者整体疾病活动度、HAQ残疾指数、SF-36 PF10及所有三项功能测试呈中-强相关。
  • Fitbit与ActiGraph步数计数一致性良好且强相关(ICC 0.96)。

临床怎么用

  • Fitbit日步数和峰值1分钟步频可用于临床实践和试验中监测肌炎患者的体力活动。

局限性

  • 试点数据,需要更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Inflammatory myopathies are characterized by muscle weakness that limits the activities of daily living. Daily step count is an accepted metric of physical activity. Wearable technologies such as Fitbit® enable tracking of daily step counts. We assessed the psychometric properties of Fitbit® and compared the accuracy of Fitbit® step counts to ActiGraph®. METHODS: This was a pilot, proof of concept, prospective observational study with four visits at 0, 1, 3 and 6 months in PM, DM, necrotizing myopathy (NM) or anti-synthetase syndrome (AS) subjects. Six core set measures (manual muscle testing, physician global disease activity, patient global disease activity, and extra-muscular disease activity, HAQ-Disability Index and creatine kinase), three functional tests (six-min walk, timed up-and-go, sit-to-stand tests) and SF-36 physical function-10 (PF10) were collected at each visit. Patients wore waist-worn Fitbit® One and ActiGraph® T3X-BT concurrently for 7 days/month for 6 months. RESULTS: Twenty-four (10 DM, 8 PM/NM, 6 AS) patients (17 females/7 males; 91% Caucasian) were enrolled. Test-retest reliability of daily steps was strong in 1-month follow-up (ICC 0.89). Daily steps and peak 1-min cadence showed moderate-strong correlations with physician global disease activity, patient global disease activity, HAQ-Disability Index, SF-36 PF10 and all three functional tests. Fitbit® and ActiGraph® step counts demonstrated good agreement and strong correlation (ICC 0.96). CONCLUSION: Fitbit® daily steps and peak 1-min cadence are reliable and valid measures of physical activity in a cohort of myositis patients. This pilot data suggests that Fitbit® has a potential for use in clinical practice and trials to monitor physical activity in myositis patients, but larger studies are needed for further validation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Saygin D, Rockette-Wagner B, Oddis C, et al. Consumer-based activity trackers in evaluation of physical activity in myositis patients. Rheumatology (Oxford). 2022. PMID: 34528065. doi:10.1093/rheumatology/keab700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。